MO-PIERIANDX
14.10.2020 14:02:03 CEST | Business Wire | Press release
PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx clinical genomic report in combination with its cancer profiling assays. Under the agreement, PierianDx will integrate the Pillar Biosciences PiVAT® bioinformatics pipeline in the PierianDx environment to provide users with an accelerated implementation, including assay-specific variant filters, to produce best-in-class clinical genomics reports and enable a complete sample-to-answer solution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005056/en/
Laboratories worldwide use Pillar Biosciences’ assays to detect pivotal genetic variants for cancer and other diseases. Pillar Biosciences’ targeted panels utilize a proprietary enrichment chemistry, SLIMamp®, that enables rapid, automated amplification of overlapping amplicons in a single tube using minimal sample inputs. Pillar Biosciences’ complementary bioinformatics pipeline, PiVAT® , is optimized for efficiency, reducing reflex testing and enabling low-frequency variant calling for every type of variant while consuming limited computing resources. PierianDx provides the Clinical Genomics Workspace™, which consists of intuitive software and a robust clinical Knowledgebase that transforms variant information into a highly-structured and comprehensive physician-ready report.
Streamlining NGS along with clinical genomic interpretation and reporting, especially for sophisticated panels, remains time-consuming and challenging. By packaging the Pillar Biosciences panels with the PierianDx report, the result will be an out-of-the-box clinical genomic report that is optimized for each assay. Furthermore, the solution will be available to customers globally through secure, and in the case of European regions, Global Data Protection Regulation (GDPR)-compliant, cloud instances. As a result, laboratories and healthcare organizations worldwide will have a highly reliable method for providing these tests to enable precision diagnostics and treatments for their patients.
“The assays from Pillar Biosciences provide robust detection for all variant types in a simplified workflow,” states Gang Song, PhD, CEO of Pillar Biosciences. “By optimizing variant filters and integrating with the PiVAT pipeline, PierianDx is streamlining interpretation and reporting, which adds substantial value for our customers.”
Rakesh Nagarajan, MD, PhD and Founder and Chief Technical and Visionary Officer of PierianDx, adds, “We are thrilled to provide this support for the Pillar Biosciences assays. As the market shifts to more sensitive assays in the LDT space and leading assay manufacturers seek in vitro diagnostic (IVD) approval, we are committed to addressing challenges that arise from even greater complexity in the interpretation and reporting process.”
About PierianDx
Founded in 2014 out of Washington University in St. Louis, PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide. Its industry-leading clinical genomics technologies, CAP and CLIA accredited laboratory, IVD-ready knowledgebase and reporting solution, and expertise deliver the most integrated, trusted, and collaborative approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx drives the adoption of genomics in clinical care and accelerates the fight against somatic cancer and hereditary germline diseases. www.pieriandx.com .
About Pillar Biosciences
Pillar Biosciences is a clinical cancer diagnostics company based in Boston, Massachusetts and Shanghai, China. Our automatable variant detection technologies deliver robust results with rapid turnaround times through streamlined NGS workflows. Our SLIMamp® – and PiVAT® -based products help high-throughput reference laboratories and clinical oncology laboratories make precision medicine practical by boosting their diagnostic productivity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005056/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press release
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duratio
Ouster Releases The REV8 OS Family: The World’s First Native Color Lidar4.5.2026 12:00:00 CEST | Press release
Powered by the Company’s breakthrough L4 and L4 Max Ouster SiliconFeatures the first patented native color lidar sensors with point for point 3D color visionIntroduces flagship OS1 Max sensor with double the range and resolution of Rev7Auto-grade, cybersecure, and designed for functional-safety Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, announced today its new family of OS digital lidar sensors, Rev8, powered by its next-generation L4 Ouster Silicon. Ouster Rev8 features the world’s first patented native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504718668/en/ The REV8 OS Family: The World's First Native Color Lidar. L4 Ouster Silicon: Ouster’s breakthrough L4 architecture doubles t
NIQ Research Reveals New Rules of Commerce: AI Is Beginning to Decide What Consumers Buy4.5.2026 12:00:00 CEST | Press release
NIQ’s latest global report—The Commerce Revolution: Where East Meets West—examines how commerce intelligence is helping brands, retailers, and platforms navigate a rapidly converging global landscapeAI is rapidly becoming the buyer, not just the tool—reshaping how products are discovered, chosen, and purchasedThe next wave of retail growth isn’t coming from traditional e‑commerce, but from live, social, quick, and AI‑driven commerce models scaling from East to West NielsenIQ (NYSE: NIQ) has announced the release of its new global report, The Commerce Revolution: Where East Meets West, which examines how Eastern-led commerce innovation and Western retail media monetization are colliding to reshape global consumer commerce. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428841965/en/ The report finds live, social, and quick commerce—long scaled across Asia—now drive most incremental digital growth worldwide, while Western m
OPAQUE Acquires Abu Dhabi-Developed Cryptographic AI Technology from TII, Extending Confidential AI Across the Full Lifecycle with Post-Quantum Protection4.5.2026 10:23:00 CEST | Press release
New capabilities make it possible to safely deploy AI agents on the most sensitive and regulated data — with hardware-enforced, verifiable rules and cryptographic guarantees built to withstand quantum computing OPAQUE, the Confidential AI company headquartered in San Francisco, California, today announced it has acquired advanced cryptographic AI technologies from the Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi's Advanced Technology Research Council (ATRC). The acquired technology — already proven in real-world use cases — adds two critical capabilities to OPAQUE's platform: confidential AI model training powered by advanced cryptographic techniques such as multi-party computation and fully homomorphic encryption, as well as post-quantum cryptographic protections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504705475/en/ OPAQUE Acquires Abu Dhabi-Developed Cryptographic AI Technology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom